Blueprint Medicines Corporation

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This study tests an experimental drug called elenestinib (BLU-263) in people with indolent systemic mastocytosis, a rare condition where too many mast cells cause symptoms like flushing, itching, and stomach issues. About 534 participants will receive either the drug or a placebo…

This study follows 80 people in Germany with indolent systemic mastocytosis whose symptoms are not well controlled by current treatments. Researchers will track how avapritinib affects quality of life and symptom control over up to 24 months in everyday medical practice. The goal…

This study looks at the long-term safety of the drug avapritinib (AYVAKIT®) in people with systemic mastocytosis who have already been taking it and benefiting from it in a previous study. About 60 participants will continue receiving the drug and be monitored for serious side ef…

This study aims to find how common the KIT D816V mutation is in people with suspected clonal mast cell disease. Researchers will collect blood samples from 450 participants and test them using two sensitive methods. The results may improve understanding and diagnosis of these rar…

This study watches how indolent systemic mastocytosis (ISM) affects people in everyday life. Researchers will collect information on symptoms, treatments, and quality of life from 150 adults. The goal is to better understand the disease and how it is managed, including the use of…